Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami, +16

Journal of Clinical Oncology

Pharmacokinetics of (glycolato-0,0?)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin

Yasutsuna Sasaki, Tomohide Tamura, Kenji Eguchi, +9

Cancer Chemotherapy and Pharmacology

Medicinal ChemistryOncology-Diammine PlatinumMedicineNew Platinum Derivative +7

Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer

Masaaki Fukuda, Tetsu Shinkai, Kenji Eguchi, +7

Cancer Chemotherapy and Pharmacology

Non-small-cell Lung CancerMedicinePhase Ii StudyAnti-cancer AgentCell Biology +6

PHOTOGRAPHIC STUDY OF SUSPENDED MATTER AND PLANKTON IN THE SEA

Satoshi Nishizawa, Masaaki Fukuda, Naoichi Inoue

Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University)

Nitrogen stable isotope ratio in the manila clam, Ruditapes philippinarum, reflects eutrophication levels in tidal flats

Satoshi Watanabe, Masashi Kodama, Masaaki Fukuda

Marine Pollution Bulletin

BiogeochemistryEutrophicationEngineeringIsotope GeochemistryRuditapes Philippinarum +8

EQCM Analysis of Redox Behavior of CuFe Prussian Blue Analog in Mg Battery Electrolytes

Shunsuke Yagi, Masaaki Fukuda, Tetsu Ichitsubo, +3

Journal of The Electrochemical Society

EngineeringElectrode-electrolyte InterfaceChemistryAqueous BatteryChemical Engineering +15

Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy.

Kenji Eguchi, Satoru Sasaki, Tomohide Tamura, +7

PubMed

ImmunologyPathologyPharmacotherapyMetronomic ChemotherapyAdvanced Malignancy +15

Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC

Yoshihiro Ohue, Koji Kurose, Takahiro Karasaki, +16

Journal of Thoracic Oncology

Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Yoshio Okano, Masahiko Ando, Kazuhiro Asami, +16

Journal of Clinical Oncology

Advanced NsclcMedicineCancer ManagementPhase Iii TrialClinical Trials +11

EQCM analysis of redox behavior of Prussian blue in a lithium battery electrolyte

Shunsuke Yagi, Masaaki Fukuda, Rie Makiura, +2

Journal of Materials Chemistry A

EngineeringElectrode-electrolyte InterfaceChemistryLi+ IonsMaterials Science +15